What is Angioslide?
Founded in 2005 by Eran Hirszowicz and Amos Nahir, Angioslide operates at the intersection of interventional cardiology and vascular surgery. The company is primarily recognized for the development and commercialization of the PROTEUS device family, which holds the distinction of being the only FDA-cleared technology designed to capture and remove embolic particles directly at the lesion site. This innovation addresses a significant clinical need in peripheral artery procedures, where the risk of distal embolization remains a primary concern for physicians. By providing a cost-effective and highly specialized solution, Angioslide has carved out a defensible niche within the medical device sector, focusing on improving patient outcomes through advanced mechanical intervention.
How much funding has Angioslide raised?
Angioslide has raised a total of $24.9M across 3 funding rounds:
Series A
$4M
Series B
$14.6M
Series C
$6.3M
Series A (2006): $4M with participation from Viola Partners
Series B (2013): $14.6M led by Triventures, Ofer-Hi Tech, and Agate Medical investments
Series C (2013): $6.3M supported by TriVentures and Viola Partners
Key Investors in Angioslide
TriVentures
A global venture capital fund specializing in early-stage healthcare breakthroughs and bio-convergence technologies, leveraging a robust network across the US, Israel, and Canada.
Viola Partners
Israel's leading technology investment group managing over $6 billion in assets, providing multi-strategy capital to support transformational technology companies.
Agate Medical Investments
A specialized investment firm focused on the medical device sector, providing strategic backing to companies developing innovative clinical solutions.
What's next for Angioslide?
With the support of major enterprise-level funding, Angioslide is well-positioned to accelerate its commercial expansion and deepen its penetration into global vascular markets. The strategic focus will likely shift toward broadening the clinical adoption of the PROTEUS platform and potentially exploring next-generation iterations of its embolic management technology. As the company matures, the emphasis will remain on maintaining regulatory excellence and demonstrating long-term clinical efficacy to healthcare providers. The backing from seasoned venture capital firms suggests a clear path toward sustained growth, with potential for further market consolidation or strategic partnerships as the company continues to address the complexities of vascular interventions.
See full Angioslide company page
